ProBio is now licensing the CHOK1 cell line development system to biopharma companies

[qocsuing2]

ProBio is now licensing the CHOK1 cell line development system to biopharma companies for commercial use

CHOK1-GenS&CHOK1-ADCC+
Cell Line Development System Commercial License

ProBio has 12 years of experience in mammalian Cell Line Development, and is one of the earliest companies getting the CHO-K1 - CHO commercial license for commercial use and sublicense agreement from ECACC.
ProBio has two cell line development systems: wild-type cell line CHOK1-GenS and ADCC-enhanced cell line CHOK1-ADCC +. CHOK1-GenS cell line development system without chemical . Developed ADCC enhanced host cell line (CHOK1-ADCC+), which can produce afucosylated monoclonal antibodies with enhanced ADCC activity. They are in together with the high-expression proprietary pGenHT 1.0-UP vector, the average titer of mAb is 5.7 g/L, the maximum titer of mAb is up to 15 g/L.

CHOK1 system exclusive advantages
IP Clear
√ ECACC license agreement
√ Proprietary pGenHT 1.0-UP vector
Royalty Free
√ One-time payment without royalty
2 CHO-K1 Host Cell License to Choose
√ Wide type CHOK1-GenS
√ ADCC enhanced CHOK1-ADCC+
Combo license at discounted price
√ Purchase in combination with wild type CHOK1-GenS cell line, and get a discounted price
Suitable for different type of proteins
√ mAb/Protein
√ BsAb,etc
Fulfill the regulatory requirements
√ Fulfill the regulatory requirements of FDA,EMA and NMPA

Case Study of CHOK1-GenS cell line system
High productivity with CHOK1-GenS system
Suitable for different type of molecules


Excellent stability with CHOK1-GenS system
The titer at the end of stability study during fed-batch is recorded as T2.
The titer at the beginning of stability study during fed-batch is recorded as T1.
Titer variation=(T2-T1)/T1*100%
Titer variation should be within 30%.


High productivity with CHOK1-GenS system
Titer prior to cell culture up to 15 g/L

Excellent Stability in Scale-Up from 3L to 200L




Case Study of CHOK1-ADCC+ cell line system
CD16a 158V/F affinity (BLI)

The affinity to CD16a (158V and 158F) was increased by 3-4 times.

PBMC-based ADCC

Cytotoxicity is increased by about 10%.
Effect concentration (EC50) was reduced by 6 times.
ADCC effect was significantly enhanced.

CHOK1 delivery package


Media Contact
Company Name: ProBio CDMO
Contact Person: ProBio CDMO
Email:
USA: cdmo.us@probiocdmo.com
China: cdmo.cn@probiocdmo.com
APAC: cdmo.apac@probiocdmo.com
Europe: cdmo.eu@probiocdmo.com
Japan: cdmo.jp@probiocdmo.com
South Korea: cdmo.kr@probiocdmo.com
Phone: 1-877-436-7274 (Toll-Free); 1-732-885-9188
Website: https://www.probiocdmo.com/